Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status
Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s ...
Zacks Investment Research on MSN13h
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago. These figures are adjusted ...
Tracking Baker Brothers Portfolio - Q4 2024 Update
Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...